Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
This article was originally published in The Pink Sheet Daily
The partners’ flexibility allows them, together and separately, to establish solid footholds in a still-evolving field with plenty of potential but also uncertainties.
You may also be interested in...
PhRMA, BIO and Abbvie also back California bill that would require pharmacists to notify physicians of biosimilar substitution while GPhA, Boehringer Ingelheim and Novartis oppose it.
After halting trials of its Rituxan biosimilar last year, Samsung Bioepis is focusing on its Enbrel biosimilar and has begun Phase I trials. Other Korean pharma are developing biosimilars of Enbrel, with Hanwha expecting approval in Korea this year.
Generic Pharmaceutical Association wants to assure legislation on biologics substitution does not impose more restrictions than required for small molecules; opposes measures pushed by Amgen and Genentech.